進行期肺癌患者の就労支援、およびその阻害因子の同定に関する研究

• Project/Area Number: 15K19159
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical sociology
• Research Institution: Aichi Cancer Center Research Institute
• Principal Investigator: 吉田 達哉 愛知県がんセンター(研究所), 分子腫瘍学部, 研究員 (10729338)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Discontinued (Fiscal Year 2016)
• Budget Amount: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: がん / 就労支援 / 肺癌 / QOL

Outline of Annual Research Achievements

研究計画の予定に沿い、進行肺癌患者の就労の状況に関する調査を予定通り進行中である。すでに100例程度の調査が終了し、その内容については、研究のサポートしていただいたがん看護専門看護師が、がん看護学会へ報告予定である。
また研究代表者の異動に伴い、科学研究費助成事業は取り消しとなるが、共同研究者と協力を行い、進行肺癌患者の就労の状況に関する調査に関するう研究は、継続中であり、来年以降も引き続きを行う予定である。

Research Products

• [Journal Article] A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin. (2016)
  • Author(s): Maeda A, Ura T, Asano C, Haｓegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A.
  • Journal Title: Asia Pac J Clin Oncol. Volume: 12 Pages: 254-258
  • Peer Reviewed / Open Access
• [Journal Article] Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. (2016)
  • Author(s): Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y.
  • Journal Title: Ｌｕｎｇ Ｃancer Volume: 97 Pages: 43-47
  • Peer Reviewed
• [Journal Article] Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. (2016)
  • Author(s): Yoshida T, Tanaka H, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T, Yatabe Y.
  • Journal Title: Lung Cancer Volume: 100 Pages: 14-19
  • Peer Reviewed
• [Journal Article] Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. (2016)
  • Author(s): Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y.
  • Journal Title: Journal of Clinical Oncology Volume: 34 Pages: 3383-3389
  • Peer Reviewed
• [Journal Article] 1.Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. (2016)
  • Author(s): Tatsuya Yoshida
  • Journal Title: Lung Cancer Volume: 1 Pages: 1-1
  • Peer Reviewed
• [Journal Article] 3.Rapid and dramatic response to alectinib in an ALK rearranged non-small-cell lung cancer patient who is critically ill. (2016)
  • Author(s): Tatsuya Yoshida
  • Journal Title: Anticancer Drugs. Volume: 1 Pages: 1-1
  • Peer Reviewed
• [Journal Article] 2.RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. (2015)
  • Author(s): Tatsuya Yoshida
  • Journal Title: Lung Cancer Volume: 90 Issue: 3 Pages: 477-483
  • DOI: 10.1016/j.lungcan.2015.09.025
  • Peer Reviewed
• [Presentation] 進行肺癌患者の就労を阻害する要因と支援の検討 (2017)
  • Author(s): 吉川 惠、吉田 達哉、大矢 由子、山田 知里、永田 智子
  • Organizer: 第31回日本がん看護学会学術集会
  • Place of Presentation: 高知県立県民文化ホール（高知市）
  • Year and Date: 2017-02-04
• [Presentation] Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small cell lung cancer (2015)
  • Author(s): Tatsuya Yoshida
  • Organizer: ESMO AISA 2015
  • Place of Presentation: シンガポール
  • Year and Date: 2015-12-18
  • Int'l Joint Research
• [Presentation] EGFR-TKI獲得耐性後におけるT790M耐性遺伝子変異とFDG/PET-CT所見の関連性の検討 (2015)
  • Author(s): 吉田 達哉
  • Organizer: 日本肺癌学会総会
  • Place of Presentation: パシフィコ横浜（横浜市）
  • Year and Date: 2015-11-26
• [Presentation] Impact of total lesion glycolysis at pretreatment FDG PET/CT on response duration of EGFR-TKIs (2015)
  • Author(s): Tatsuya Yoshida
  • Organizer: European Cancer Congress
  • Place of Presentation: オーストリア ウィーン
  • Year and Date: 2015-09-25
  • Int'l Joint Research
• [Presentation] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients (2015)
  • Author(s): Tatsuya Yoshida
  • Organizer: European Cancer Congress
  • Place of Presentation: オーストリア ウィーン
  • Year and Date: 2015-09-25
  • Int'l Joint Research
• [Presentation] The impact of crizotinib on brain metastasis in ALK-positive NSCLC patients (2015)
  • Author(s): Tatsuya Yoshida
  • Organizer: 日本臨床腫瘍学会
  • Place of Presentation: 札幌
  • Year and Date: 2015-07-16